Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eloxx adds additional treatment arm to ongoing Phase 2 Cystic Fibrosis studies » 16:52
04/29/21
04/29
16:52
04/29/21
16:52
ELOX

Eloxx Pharmaceuticals

$2.15 /

-0.025 (-1.15%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis, CF, in patients with at least one G542X allele. The Phase 2 clinical program now includes a fifth treatment arm to evaluate safety of ELX-02 in combination with Kalydeco, an FDA-approved CFTR potentiator for the treatment of cystic fibrosis in patients who have at least one mutation in their CF gene amenable to ivacaftor. The Phase 2 trials are designed to evaluate the safety of ELX-02 and assess its biological activity. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR gene.

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$2.15 /

-0.025 (-1.15%)

ELOX Eloxx Pharmaceuticals
$2.15 /

-0.025 (-1.15%)

04/01/21 Piper Sandler
Eloxx Pharmaceuticals acquires Zikani in all-stock deal, says Piper Sandler
06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
ELOX Eloxx Pharmaceuticals
$2.15 /

-0.025 (-1.15%)

Hot Stocks
Advent Life Sciences reports 6.3% stake in Eloxx Pharmaceuticals » 14:15
04/13/21
04/13
14:15
04/13/21
14:15
ELOX

Eloxx Pharmaceuticals

$2.65 /

-0.05 (-1.85%)

Advent Life Sciences…

Advent Life Sciences disclosed a 6.3% stake in Eloxx Pharmaceuticals, which represents over 2.5M shares. The filing with the SEC allows for activism. Advent said it bought the shares for investment purposes.

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$2.65 /

-0.05 (-1.85%)

ELOX Eloxx Pharmaceuticals
$2.65 /

-0.05 (-1.85%)

04/01/21 Piper Sandler
Eloxx Pharmaceuticals acquires Zikani in all-stock deal, says Piper Sandler
06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
ELOX Eloxx Pharmaceuticals
$2.65 /

-0.05 (-1.85%)

Over a month ago
Recommendations
Eloxx Pharmaceuticals acquires Zikani in all-stock deal, says Piper Sandler » 12:53
04/01/21
04/01
12:53
04/01/21
12:53
ELOX

Eloxx Pharmaceuticals

$3.28 /

+0.01 (+0.31%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $6 price target on Eloxx Pharmaceuticals shares after the company acquired Zikani Therapeutics in an all-stock transaction. The combined company will initially focus on developing oral RMAs in rare orphan skin disease, Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa with an IND filing expected in 2022, Tenthoff tells investors in a research note. The analyst now expects Phase II ELX-02 cystic fibrosis patients not addressable data in 2H21.

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.28 /

+0.01 (+0.31%)

ELOX Eloxx Pharmaceuticals
$3.28 /

+0.01 (+0.31%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.28 /

+0.01 (+0.31%)

Hot Stocks
Eloxx Pharmaceuticals trading resumes  08:15
04/01/21
04/01
08:15
04/01/21
08:15
ELOX

Eloxx Pharmaceuticals

$3.35 /

+0.32 (+10.56%)

 
ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

Hot Stocks
Eloxx Pharmaceuticals to acquire Zikani Therapeutics in all-stock transaction » 07:47
04/01/21
04/01
07:47
04/01/21
07:47
ELOX

Eloxx Pharmaceuticals

$3.35 /

+0.32 (+10.56%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced it has acquired Zikani Therapeutics in an all-stock transaction, with the potential to create a leader in ribosomal RNA-targeted therapies for treatment of rare diseases and oncology. Sumit Aggarwal, previously the President and CEO of Zikani, has been named President and CEO of Eloxx, and Vijay Modur, M.D., Ph.D., who was Zikani's Chief Scientific and Medical Officer, has been named Eloxx's Head of Research and Development. ELX-02 is currently in Phase 2 clinical trials in Cystic Fibrosis patients affected by nonsense mutations in the cystic fibrosis transmembrane conductance regulator gene. The investigational therapy has shown strong activity across a full range of mutations in CF preclinical models. In Phase 1 testing, ELX-02 was generally well- tolerated and demonstrated high bioavailability with consistent pharamacokinetics across both single and multiple-dose studies. In addition to CF, the company plans to file an IND in 2022 for what could potentially become the first oral therapy for protein restoration for patients with nonsense mutations in Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa. RDEB is an incurable, extremely painful and often fatal skin blistering condition caused by a lack of collagen type VII that is estimated to affect more than 3,000 people worldwide. JEB is the most severe form of EB, with most patients dying in infancy. By extending the application of ribosomal RNA modulation to the readthrough of nonsense mutations in tumor suppressor genes, the company is also rapidly advancing preclinical research for familial adenomatous polyposis, an inherited pre-cancerous colorectal disease frequently caused by nonsense mutations in the adenomatous polyposis coli gene. Nonsense mutations cause approximately 10-12 percent of rare inherited diseases. ELX-02 along with the TURBO-ZM library of compounds are anticipated to significantly expand to include the treatment of many other rare diseases and certain cancers. Under the terms of the merger agreement, stockholders of Zikani received approximately 7.6 million Eloxx common shares and own approximately 16 percent of the combined company. In connection with the acquisition, Silvia Noiman, Ph.D., and Martijn Kleijwegt have stepped down from the Eloxx Board. Alan Walts, Ph.D., and Raj Parekh, Ph.D., who have both served as Zikani directors, were appointed to fulfill the vacancies and serve out the remaining terms of office.

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

Hot Stocks
Eloxx Pharmaceuticals trading halted, news pending  07:43
04/01/21
04/01
07:43
04/01/21
07:43
ELOX

Eloxx Pharmaceuticals

$3.35 /

+0.32 (+10.56%)

 
ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.35 /

+0.32 (+10.56%)

Over a quarter ago
Hot Stocks
Eloxx Pharmaceuticals' ELX-02 featured in Journal of Cystic Fibrosis » 07:15
02/09/21
02/09
07:15
02/09/21
07:15
ELOX

Eloxx Pharmaceuticals

$3.98 /

+0.18 (+4.74%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced that a scientific manuscript published in the Journal of Cystic Fibrosis presented the results of Eloxx's evaluation of ELX-02 mediated read-though, using the CFTR-dependent Forskolin-induced swelling assay across a selection of G542X homozygous and heterozygous patient-derived organoids. ELX-02 increased CFTR activity in a dose-dependent fashion across a variety of forskolin induction concentrations.The functional increases are similar to those obtained with tezacaftor/ivacaftor in an F508del homozygous organoid. These data support Eloxx's current Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with G542X nonsense alleles. Eloxx expects to report top line data in the first half of 2021.

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.98 /

+0.18 (+4.74%)

ELOX Eloxx Pharmaceuticals
$3.98 /

+0.18 (+4.74%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.98 /

+0.18 (+4.74%)

Hot Stocks
Eloxx Pharmaceuticals announces publication of manuscript on ELX-02 » 07:05
01/26/21
01/26
07:05
01/26/21
07:05
ELOX

Eloxx Pharmaceuticals

$3.93 /

+ (+0.00%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced that a scientific manuscript titled: "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects" was published in the Journal of Clinical Pharmacology in Drug Development. "We are very pleased that our scientific manuscript on the results of our Phase 1B multiple-ascending dose trial evaluating the safety and pharmacokinetics of ELX-02 in healthy volunteers has been published in the Journal of Clinical Pharmacology in Drug Development," said Dr. Matthew Goddeeris, PhD, Vice President of Research, Eloxx Pharmaceuticals. "There were no severe or serious adverse events reported in the trial, which is consistent with the favorable tolerability profile demonstrated across our preclinical and clinical datasets. These data support our current Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with nonsense alleles, for whom there are few, if any, treatment options available. We look forward to reporting top line data in the first half of 2021."

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.93 /

+ (+0.00%)

ELOX Eloxx Pharmaceuticals
$3.93 /

+ (+0.00%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.93 /

+ (+0.00%)

Hot Stocks
Eloxx Pharmaceuticals announces publication of manuscript on ELX-02 » 07:08
01/20/21
01/20
07:08
01/20/21
07:08
ELOX

Eloxx Pharmaceuticals

$4.08 /

-0.06 (-1.45%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced that a scientific manuscript titled: "Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients," has been published in the Journal of Clinical Pharmacology. "We are pleased that our scientific manuscript on the results of our Phase 1 renal impairment trial which defined the relationship of eGFR and drug exposure and urinary clearance in patients with renal impairment has been published in the Journal of Clinical Pharmacology," said Dr. Thomas Haverty, CMO at Eloxx Pharmaceuticals. "ELX-02 was well tolerated by patients with renal insufficiency and nephropathic cystinosis patients and exhibits a consistent pharmacokinetic profile across increasing degrees of renal insufficiency with reduced clearance, increased exposure, and prolonged renal elimination proportional to eGFR. The data from the renal impairment study enabled the development of an eGFR-PK model of ELX-02 which was successfully used to implement individualized daily dosing of ELX-02 in a Phase 2a study in patients with nephropathic cystinosis to achieve a weekly targeted exposure." These results further support our ongoing Phase 2 program in cystic fibrosis and IND-enabling studies in autosomal dominant polycystic kidney disease."

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$4.08 /

-0.06 (-1.45%)

ELOX Eloxx Pharmaceuticals
$4.08 /

-0.06 (-1.45%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$4.08 /

-0.06 (-1.45%)

Hot Stocks
Eloxx says CF Foundation to provide increased funding for ELX-02 trial » 09:05
01/13/21
01/13
09:05
01/13/21
09:05
ELOX

Eloxx Pharmaceuticals

$4.30 /

+ (+0.00%)

Eloxx Pharmaceuticals…

Eloxx Pharmaceuticals announced an expansion of its agreement with the CF Foundation beyond the U.S. portion of the trial to include additional funding for the global clinical trial program which includes Europe and Israel. The company said, " Our Phase 2 program consists of two trials, one currently enrolling patients at sites in Europe and Israel and the second in the U.S. In the U.S., in addition to the partial funding being provided by the CF Foundation, our protocol has been sanctioned by the Cystic Fibrosis Therapeutics Development Network. In Europe, the European Cystic Fibrosis Society Clinical Trial Network has given our trial a "high priority" ranking. Dr. Ahmet Uluer, Director of the Adult Cystic Fibrosis Program at the Boston Children's Hospital/Brigham and Women's Hospital CF Center, is the lead study investigator in the U.S. We expect to report top line data from our proof of concept Phase 2 program in the first half of 2021, which is contingent on no further disruptions due to COVID-19. The Safety Review Committee has held several planned meetings and approved dose escalation up to the highest dose level. To date, we have had no reported serious adverse events in the clinical trial. We are participating in the European HIT-CF consortium to support the collection of cystic fibrosis patient-derived organoids and the initiative to conduct a prospective clinical trial to confirm the translational potential of the organoid model. The intent of the program is to use these positive results to enroll patients with responsive organoids in a prospective trial with ELX-02. We believe this program will continue to expand the application of organoid technology from drug discovery through drug approval, and also offers possible label expansion opportunities. "

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$4.30 /

+ (+0.00%)

ELOX Eloxx Pharmaceuticals
$4.30 /

+ (+0.00%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$4.30 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.